Rentosertib, a drug developed by Insilico Medicine for idiopathic pulmonary fibrosis, made patients appear biologically younger in a clinical trial using aging clocks. Rentosertib, an AI-discovered drug for idiopathic pulmonary fibrosis, made patients appear three to four years biologically younger in a clinical trial. A drug being developed to treat a serious lung disease may also help to slow the aging process, researchers say. In a small clinical study, patients who took rentosertib – developed by Insilico Medicine in Massachusetts – showed changes in blood proteins that made them appear biologically younger. Several tests estimated that after treatment, the patients were biologically about three to four years younger. The results were based only on changes in proteins in their blood, and do not yet support the use of rentosertib as an anti-aging treatment. The risks and side effects associated with rentosertib were found to be "manageable," according to Dr. Carol Ann Satler, senior vice president of clinical development for Insilico Medicine. This means it’s possible that the improvements in the participants’ lung disease was related to the changes in blood proteins. Larger and longer trials – including healthy older adults and populations without IPF – are needed to determine whether the drug truly has anti-aging effects and whether they could lead to better health.

Original title: “Experimental lung disease drug may slow aging by 3-4 years, study suggests | Fox News”

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS ... Advanced Therapy (RMAT) designation to RXRG001 for the treatment of radiation-induced xerostomia (RIX) and hyposalivation. The designation was granted based on preliminary clinical evidence from the ongoing Phase 1/2a SPRINX-1 Study. RXRG001 is being evaluated in a first-in-human, multi-center Phase 1/2a clinical trial in adults ... SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--RiboX Therapeutics (“RiboX”), a clinical-stage biotechnology company pioneering the discovery and development of fully engineered circular RNA (circRNA) therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RXRG001 for the treatment of radiation-induced xerostomia (RIX) and hyposalivation. The designation was granted based on preliminary clinical evidence from the ongoing Phase 1/2a SPRINX-1 Study. RXRG001 is being evaluated in a first-in-human, multi-center Phase 1/2a clinical trial in adults with radiation-induced xerostomia and hyposalivation ongoing in the US. RMAT designation is an FDA program designed to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse or cure serious or life-threatening diseases or conditions. To qualify, a therapy must have preliminary clinical evidence indicating the potential to address unmet medical needs. RiboX is a clinical-stage biotechnology company pioneering the discovery and development of fully engineered circular RNA therapeutics to address unmet medical needs across a broad range of diseases. The company’s proprietary circular RNA technology and delivery platforms are designed to enable durable protein expression and unlock the therapeutic potential of RNA medicines. The RMAT designation was supported by preliminary clinical data from SPRINX-1 (NCT06714253), an ongoing first-in-human, multicenter Phase 1/2a study evaluating the safety, tolerability and preliminary efficacy of RXRG001 administered directly into the parotid gland ducts in adults with RIX and hyposalivation. RXRG001 is a proprietary circular RNA therapeutic encoding human aquaporin-1 (hAQP1), a water-channel protein involved in fluid transport, encapsulated in a lipid nanoparticle (LNP).

Original title: “RiboX Therapeutics Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RXRG001 for the Treatment of Radiation-Induced Xerostomia and Hyposalivation - BioSpace”

Structure Therapeutics’ oral GLP-1 candidate aleniglipron showed 72-week efficacy “in line” with Novo Nordisk’s oral Wegovy, BMO Capital Markets wrote in a note to investors. Meanwhile, Structure’s amylin and calcitonin receptor agonist ACCG-2671 showed “impressive” target engagement in a Phase 1 trial of healthy volunteers, according to Leerink Partners.

Original title: “Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop”

08, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with ... 08, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product and product candidates, the availability and success of topline results from our ongoing clinical trials, any commercial potential of our product and product candidates following applicable regulatory approvals and the outcome of any pending litigation. About the PHrontier Study The Phase 3 PHrontier clinical study is a randomized (1:1), double-blind, placebo-controlled, global trial evaluating the safety and efficacy of mosliciguat in adult patients with PH-ILD. The study is currently designed to enroll approximately 375 patients worldwide. About Pulmonary Hypertension and Interstitial Lung Disease Pulmonary hypertension (PH) is a progressive and debilitating condition characterized by high blood pressure in the blood vessels of the lungs. It is a terrific example of the Roivant model working as planned: finding high-potential molecules and going after diseases where the patient needs are enormous and where the drug can truly shine.” · “Our robust Phase 2 PHocus study results, in conjunction with mosliciguat’s inhaled, once-a-day administration and potential first-in-class sGC activator profile, strongly position it as a potential single agent treatment and combination therapy for patients with PH-ILD.

Original title: “Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study - BioSpace”

The approval opens up a “modest” market for AstraZeneca’s Etcamah, according to Leerink analysts, who nevertheless looked forward to an upcoming late-stage readout that could lead to a “significantly larger opportunity” for the drug.

Original title: “AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer”

The failure of Novartis’ pelacarsen to translate its Lp(a)-lowering effects to clinical benefits “marks a meaningful setback” for other companies taking a similar approach to cardiovascular risk, analysts say—including Eli Lilly and Amgen.

Original title: “Novartis’ cholesterol-lowering medicine fails Phase 3, clouding Lp(a) horizons”

DelveInsight s Minimal Residual Disease Pipeline Insight 2026 report provides comprehensive insights about 5 companies and 5 pipeline drugs in the Minimal Residual Disease pipeline landscape It covers the Minimal Residual Disease Pipeline drug profiles including clinical and nonclinical stage ... Press release - DelveInsight Business Research LLP - Minimal Residual Disease Clinical Trial Pipeline Gains Momentum: 5+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - published on openPR.com • Minimal Residual Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination • Minimal Residual Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Discover what's next for the Minimal Residual Disease Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/minimal-residual-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr Table of Contents 1. The Hepatitis C Virus market is expected to witness a major change during the forecast period, driven by rising disease awareness, incremental healthcare spending worldwide, and the continued advancement of direct-acting antiviral (DAA) therapies. As drug manufacturers work to penetrate further into the market, the launch of emerging therapies is set to significantly reshape the HCV treatment landscape. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Minimal residual disease. If you're tracking ongoing Minimal Residual Disease Clinical trials, this press release is a must-read @ https://www.delveinsight.com/sample-request/minimal-residual-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr The Minimal Residual Disease Pipeline report provides insights into:- • The report provides detailed insights about companies that are developing therapies for the treatment of Minimal Residual Disease with aggregate therapies developed by each company for the same.

Original title: “Minimal Residual Disease Clinical Trial Pipeline Gains Momentum: 5+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight”

X4 Pharmaceuticals is a company ... with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating ... X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. “With an estimated 15,000 patients experiencing serious and/or recurring infections as a result of their chronic neutropenia, we continue to believe mavorixafor can address a significant market opportunity based on its unique value proposition for the treatment of this rare disease with very limited therapy options,” concluded Dr. Craig. ... The 4WARD trial is a global, pivotal Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of oral, once-daily mavorixafor (with or without G-CSF) in patients with congenital, acquired primary autoimmune, or idiopathic chronic neutropenia who are experiencing recurrent and/or serious infections. - FDA Agrees to Reduced Sample Size for the Global 4WARD Phase 3 Chronic Neutropenia Trial - - Expect Completion of Enrollment by Year-End 2026 and... X4 Pharmaceuticals Hematology FDA Clinical Trials Oncology GlobeNewswire · September 01, 2026 16:30 ET | Source: X4 Pharmaceuticals · X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on...

Original title: “X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting”

The U.S. Food and Drug Administration today expanded treatment options for adult patients with advanced breast cancer, reflecting the FDA’s commitment to advancing medical innovation and getting new treatments to patients who need them.

Original title: “FDA Grants Accelerated Approval to a New Breast Cancer Treatment”